Larimar Therapeutics Inc (LRMR)
EBITDA Growth
-73.24%
TTM · Period ending:
LRMR EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-73.24%period ending
Latest reported-73.24%period ending
LRMR TTM EBITDA YoY % (-44.44% → -73.24%)
Year-over-year change
High-resolution chart · PNG
LRMR ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -73.2395% | |
| -74.5735% | |
| -105.9176% | |
| -104.2777% | |
| -71.4414% | |
| -112.0119% | |
| -119.1331% | |
| -94.875% | |
| -79.4543% | |
| -37.2119% | |
| -4.5695% | |
| 4.7875% | |
| 25.184% | |
| 30.8169% | |
| 30.3827% | |
| 37.5566% | |
| 12.1677% | |
| 1.8217% | |
| -18.0051% | |
| -61.5168% | |
| -50.1526% | |
| -91.4959% | |
| -84.3404% | |
| -9.9754% | |
| 12.6154% | |
| 49.1948% | |
| 62.4556% | |
| 48.8543% | |
| 36.7574% | |
| 13.784% | |
| -15.9722% | |
| -23.724% | |
| -15.1609% | |
| -8.0272% | |
| 7.7676% | |
| 28.7985% | |
| 30.7986% | |
| 31.107% | |
| 21.1381% | |
| -6.5454% | |
| -44.4356% |